Immunotherapy trial for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new immunotherapy drug (STC-1010) for people with colorectal cancer that cannot be removed by surgery or has spread. It aims to see if the drug can shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have colorectal cancer that cannot be removed with surgery or has spread to other parts of the body.
- You have not had chemotherapy for metastatic disease before, and at least 6 months have passed since any prior chemotherapy after surgery.
- You have a tumor that can be measured on scans, and you are willing to have biopsies (tissue samples) before and during treatment if safe.
- You are in good overall health (able to care for yourself) and your life expectancy is more than 3 months.
- You do not have certain autoimmune diseases, a BRAF mutation, or other conditions that would interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests CYAD-101, an immune-cell treatment made from donor T-cells, given with standard chemotherapy. It is for people with colon or rectal cancer that has spread and has not responded to prior treatments.
This trial tests a combination of four drugs (SX-682, TriAdeno vaccine, retifanlimab, and N-803) to see if they can help people with colorectal cancer that has spread. It may be an option if you have already tried at least two standard treatments or cannot take them.
This trial tests a combination of targeted radiation therapy, an immune-boosting drug, and two chemotherapy drugs for colorectal cancer that has spread or come back after two rounds of prior treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of radiation therapy, an immunotherapy drug (QL1706), and two targeted drugs (TAS-102 and bevacizumab) for people with advanced colorectal cancer that has spread and is not removable by surgery. It aims to see if this combination can help shrink tumors or slow cancer growth.
This trial tests a combination of a targeted therapy pill (TKI) and an immunotherapy (PD-1 inhibitor) for people with advanced colorectal cancer that has stopped responding to standard treatments. It uses a blood test to tailor the treatment, aiming to be more effective with fewer side effects.
This trial tests a new drug called SOT109 for people with advanced colorectal cancer that can't be removed by surgery or has spread. The goal is to see if it is safe, how well it works, and how the body handles it.
Hear when a new Unresectable Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.